Nov 03, 2009 (M2 PRESSWIRE via COMTEX News Network) --

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Friday, November 6th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and November earnings reports. DUSA Pharmaceuticals (NASDAQ:DUSA) and Rediff.com India (NASDAQ:REDF) are both expected to be lower after their earnings are released Friday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go lower after earnings are released Friday:

Symbol Company # of Reports Quarter Release Time

DUSA DUSA Pharmaceuticals 12 quarters Q3 Before

REDF Rediff.com India Limit 12 quarters Q2 Before

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA), an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, ClindaReach, Meted, and Psoriacap products. DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts.

 Continued...